Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avadel Pharmaceuticals PLC
Income from Continuing Operations
Avadel Pharmaceuticals PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Income from Continuing Operations
-$278k
|
CAGR 3-Years
87%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
42%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Income from Continuing Operations
-$1.4B
|
CAGR 3-Years
-120%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Income from Continuing Operations
-$357.5m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Income from Continuing Operations
-$48.3m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-155%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Income from Continuing Operations
-€3.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Income from Continuing Operations
-€3k
|
CAGR 3-Years
92%
|
CAGR 5-Years
72%
|
CAGR 10-Years
54%
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Income from Continuing Operations?
Income from Continuing Operations
-278k
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Income from Continuing Operations amounts to -278k USD.
What is Avadel Pharmaceuticals PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
42%
Over the last year, the Income from Continuing Operations growth was 100%. The average annual Income from Continuing Operations growth rates for Avadel Pharmaceuticals PLC have been 87% over the past three years , and 42% over the past ten years .
